Kaihara A, Iwagaki H, Gouchi A, Hizuta A, Isozaki H, Takakura N, Tanaka N
First Department of Surgery, Okayama University Medical School, Japan.
Res Commun Mol Pathol Pharmacol. 1998 Jun;100(3):283-300.
Intercellular adhesion molecule-1 (ICAM-1), a molecule bound to the cell surface, is a ligand for leukocyte function antigen-1 (LFA-1), and the ICAM-1/LFA-1 system mediates various cell-cell interactions involved in immunity. Soluble ICAM-1 (sICAM-1) is a circulating substance and binds with LFA-1 of leukocytes, thus, making leukocytes less available for binding with cell surface ICAM-1 on target cells. The serum level of soluble ICAM-1 (sICAM-1) was found to be significantly elevated (p<0.01) in patients with early and advanced gastric cancer compared with healthy controls. Natural killer activity (NK activity) was assessed by measuring the cytotoxicity of peripheral blood mononuclear cells (PBMCs) for K562 cells. There was no significant difference in NK activity between gastric cancer patients and healthy controls when heat-inactivated fetal calf serum was used in assays. However, addition of patient serum significantly decreased (p<0.05) NK activity when the serum was from patients with advanced gastric cancer compared with healthy volunteers. Addition of anti-ICAM-1 monoclonal antibody 0 to 5.0 microg/ml caused little change in NK activity in healthy controls, but its addition at 10 microg/ml remarkably decreased NK-activity in gastric cancer patients, probably through antibody binding with ICAM-1 on target cells. In other experiments, liver metastasis was induced in mice by inoculation of colon 26 murine colon cancer cells. In vitro pretreatment of colon 26 cells with the anti-ICAM-1 monoclonal antibody significantly increased the number of metastatic nodules. These results suggest that both sICAM-1 and anti-ICAM-1 monoclonal antibody act as immunosuppressive factors by inhibiting the ICAM-1/LFA-1 system.
细胞间黏附分子-1(ICAM-1)是一种结合于细胞表面的分子,是白细胞功能抗原-1(LFA-1)的配体,ICAM-1/LFA-1系统介导了多种参与免疫的细胞间相互作用。可溶性ICAM-1(sICAM-1)是一种循环物质,可与白细胞的LFA-1结合,从而使白细胞与靶细胞表面ICAM-1的结合减少。研究发现,与健康对照相比,早期和晚期胃癌患者的血清可溶性ICAM-1(sICAM-1)水平显著升高(p<0.01)。通过测量外周血单个核细胞(PBMC)对K562细胞的细胞毒性来评估自然杀伤活性(NK活性)。当在检测中使用热灭活胎牛血清时,胃癌患者和健康对照的NK活性没有显著差异。然而,与健康志愿者相比,当血清来自晚期胃癌患者时,添加患者血清显著降低了(p<0.05)NK活性。添加0至5.0微克/毫升的抗ICAM-1单克隆抗体对健康对照的NK活性影响不大,但在胃癌患者中添加10微克/毫升时,显著降低了NK活性,这可能是通过抗体与靶细胞上的ICAM-1结合实现的。在其他实验中,通过接种结肠26小鼠结肠癌细胞诱导小鼠发生肝转移。用抗ICAM-1单克隆抗体对结肠26细胞进行体外预处理显著增加了转移瘤结节的数量。这些结果表明,sICAM-1和抗ICAM-1单克隆抗体均通过抑制ICAM-1/LFA-1系统而作为免疫抑制因子发挥作用。